Current applications of biomarkers in cardiomyopathies

Related Experiment Video

Updated: Apr 8, 2026

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

17.2K

Caroline J Coats1, Wendy E Heywood, Kevin Mills

  • 1Institute of Cardiovascular Science, The Heart Hospital, 16-18 Westmoreland Street, London W1G 8PH, UK.

Expert Review of Cardiovascular Therapy
|June 25, 2015
PubMed

Insights

Cardiomyopathies can cause sudden death and heart failure. This review covers key biochemical markers for diagnosing and managing these heart muscle diseases, including new discovery methods.

Area of Science:

  • Cardiology
  • Biochemistry
  • Genetics

Background:

  • Cardiomyopathies are a significant cause of sudden cardiac death, arrhythmias, and heart failure across all age groups.
  • While many cardiomyopathies have an inherited basis, biochemical markers are crucial for diagnosis and prognosis.
  • Effective patient management relies on understanding the role of these markers.

Purpose of the Study:

  • To review the rationale and evidence for key biomarkers in cardiomyopathy patient management.
  • To discuss the application of biochemical markers in the diagnostic work-up of cardiomyopathies.
  • To explore emerging biomarkers and novel approaches to their discovery.

Main Methods:

  • Literature review of existing studies on cardiomyopathy biomarkers.
  • Analysis of the role of biochemical markers in patient diagnosis and prognosis.
  • Discussion of current and future trends in biomarker discovery.

Main Results:

  • Biochemical markers are fundamental to the diagnostic work-up of cardiomyopathies.
  • These markers aid in the prognostic assessment of disease severity and progression.
  • Emerging biomarkers and advanced discovery techniques are enhancing diagnostic capabilities.

Conclusions:

  • Biochemical markers play a vital role in the comprehensive management of cardiomyopathies.
  • Continued research into novel biomarkers is essential for improving patient outcomes.
  • Understanding biomarker evidence supports clinical decision-making in cardiology.

Keywords:
biomarkerscardiomyopathymyocardialnatriuretic peptidestroponin

More Related Videos

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes13:42

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes

Published on: March 8, 2013

12.4K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.8K

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.2K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
773
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
748
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
451
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
835
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
784